

Clinical criteria remain paramount for the diagnosis of polycystic ovary syndrome in the adolescent age group



A Weinberg^{1,2}, M Phillip^{1,2}, L de Vries^{1,2}

¹Institute for Endocrinology and Diabetes, National Center of Childhood Diabetes, Schneider Children's Medical Center of Israel, Petah Tiqwa, Israel.

²Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.



מרכז נפישון ילדים לרפואה
מרכז מדיקלי לילדים והנוער
Schneider Children's Medical Center of Israel
Member of Clalit Health Services

Introduction

Adolescent polycystic ovary syndrome (PCOS) may be difficult to distinguish from pubertal changes and diagnosis remains a challenge. Identifying girls at risk for PCOS and implementing treatment early in the development of PCOS may be an effective means of preventing some of the long-term co-morbidities such as the metabolic syndrome and infertility.

Aim

- To investigate the value of different biochemical parameters for the diagnosis of PCOS in adolescents.
- To assess the prevalence of non-classical congenital adrenal hyperplasia (NCCAH) among adolescent girls referred for clinical symptoms suggesting PCOS.

Method and Subjects

- Design** A retrospective, cross-sectional study at a tertiary pediatric endocrinology unit.
- Study cohort** 114 girls aged 13-18 with a clinical presentation suggesting PCOS who underwent GnRH and ACTH stimulation tests.
- Clinical and laboratory characteristics of girls diagnosed with PCOS (based on Rotterdam criteria) were compared to those of girls having "isolated" hyperandrogenism or menstrual irregularities ("non-PCOS").

Results

- 9 of 114 girls (7.9%) were diagnosed with NCCAH, 87 with PCOS (53 met all 3 Rotterdam criteria), 18 were non-PCOS.
- Hormonal profile** - Androstenedione, basal LH and basal LH/FSH ratio were significantly higher in girls with PCOS, but overlap between groups was observed.
- Clinical presentation** - girls with PCOS had a significantly higher prevalence of hirsutism, PCO morphology by ultrasonography, and menstrual irregularities.
- Comparisons of only PCOS girls who met all 3 Rotterdam criteria (n=53) to the non-PCOS group, yielded similar results.
- Using stepwise logistic regression, the only predictive factor for PCOS was the basal LH/FSH ratio, with insufficient sensitivity and specificity.

	PCOS (n=87)	Non -PCOS (n=18)	P value
Clinical features			
Age at first evaluation (y)	15.3±1.3	15.9±1.6	0.08
Mean systolic blood pressure	114±10	118±13	0.26
Mean diastolic blood pressure	67.2±8.9	70.9±10.0	0.16
Birth weight (Kg)	3.04±0.55	3.48±0.37	0.06
Anthropometric measurements			
Height SDS	-0.22±0.1	-0.13±1.18	0.71
Weight SDS	0.53±1.08	0.84±1.31	0.28
BMI SDS	0.66±1.05	0.91±1.26	0.38
Hormonal profile			
DHEA-S (µmol/l)	5.82±3.14 (0.8-17.4)	4.99±2.81 (0.5-8.8)	0.33
Androstenedione (nmol/l)	7.46±2.99 (2.5-15.1)	5.43±2.24 (2.6-9.9)	0.009
Testosterone (nmol/l)	1.38±0.81 (0.3-5.0)	1.10±0.73 (0.3-2.7)	0.18
Basal 17-OHP (nmol/l)	2.62±1.50	2.93±1.50	0.45
Stimulated 17-OHP (nmol/l)	8.11±3.34	8.67±2.99	0.54
Basal LH (IU/L)	7.36±4.62 (0.6-18.5)	4.38±3.08 (0.4-14.3)	0.01
Basal FSH (IU/L)	5.49±1.90 (1.0-11.4)	5.64±2.35 (1.1-9.5)	0.77
Basal LH/FSH ratio	1.34±0.71 (0.2-3.3)	0.78±0.40 (0.3-1.8)	0.001
Peak LH (IU/L)	50.6±40.9 (9.4-200)	33.7±26.4 (4.7-95.5)	0.13
Peak FSH (IU/L)	10.4±4.4 (3.8-25.0)	10.1±4.3 (4.9-20.5)	0.86
Peak LH/FSH ratio	4.7±2.9 (0.8-20.6)	3.7±3.3 (0.4-14.1)	0.22
Prolactin (ng/ml)	10.45±5.71	8.48±4.37	0.22
Fasting glucose (mg/dL)	82.4±9.7	83.9±6.0	0.56
Total cholesterol (mg/dL)	157.0±27.7	161.9±17.2	0.55
Triglycerides (mg/dL)	84.2±39.9	87.6±33.0	0.77
LDL (mg/dL)	87.7±22.9	97.8±16.7	0.16
HDL (mg/dL)	52.2±14.1	48.7±12.4	0.44
Clinical presentation			
Hirsutism	72 (85.7%)	9 (52.9%)	0.001
Menstrual irregularity	82 (95.3%)	10 (55.6%)	<0.001
PCO morphology - sonography	57 (73.1%)	0 (0%)	<0.001

Conclusions

- While an increased basal LH and basal LH/FSH ratio may support the diagnosis of PCOS in adolescents, the GnRH stimulation test is not contributory.
- Given the significant prevalence of NCCAH among adolescents presenting as PCOS, an ACTH test should be included in the work-up, at least in populations with higher prevalence.
- Since no one parameter is diagnostic for PCOS, clinical criteria remain paramount.

